Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
27 Cards in this Set
- Front
- Back
Goal blood glucose target in ICU
|
< 180mg/dl
|
|
T/F. Regularly scheduled administration of insulin is preferable to bolus insulin in ICU
|
True, proactive approach is preferable to reactive approach
|
|
When should glucose be monitored in ICU
|
every 1 - 2 hours until stable, then every 4 hours
|
|
Drug therapy for stress ulcer is indicated for patients with what risk factors
|
1) respiratory failure requiring mechanical ventilation
2) coagulopathy - platelet < 50,000, inr > 1.5, apt > 2 times control (patients on anticoagulants is not a coagulopathy) |
|
Which class of meds has been shown clearly in clinical trials for stress ulcer prophylaxis
|
H2 antagonists
|
|
What is recommended method of administration of H2 blockers in stress ulcer prophylaxis
|
Evidence of effect is IV however they are administered enterally when possible due to excellent bioavailability
|
|
Despite limited evidence this class is used for stress ulcer prophylaxis
|
PPI (enterally administered - limited evidence, IV has no evidence)
|
|
Complications of acid suppression therapy in stress ulcer prophylaxis
|
pneumonia
C. Diff |
|
Which agents are NOT recommended for stress ulcer prophylaxis
|
Antacids, sucralfate
|
|
Adverse effects of H2 blockers in stress ulcer prophylaxis
|
mental status changes
Thrombocytopenia (cimetidine) |
|
Doses of h2 blockers in SUP
|
drug po iv
ranitidine 150mg q12 50mg q8 famotidine 20mg 20mg q12 cimetidine 300mg q6 300mg q6 or 37.5-50mg ci nizatidine 150mg q12 |
|
Only H2 blocker FDA approved for SUP
|
cimetidine
|
|
PPI pharmacology and mechanism of action
|
prodrugs that are activated in the acidic environment of the parietal cell that then bind to active proton pumps. Oral formulations are designed to dissolve at pH > 5.6 to protect from degradation and premature activation in the stomach
|
|
Which PPI formulation should not be administered via NG/OGT
|
lansoprazole delayed release suspension which has xanthan gum in formulation
|
|
What is the only PPI formulation FDA approved for SUP
|
Zegerid powder for oral suspension 20mg
|
|
Adverse Effects of PPI's in SUP
|
Headache, diarrhea, constipation, abdominal pain, nausea
|
|
Disadvantages of PPI in SUP
|
Risk for Clostridium Difficile, and pneumonia, cost, Drug interaction (inhibit conversion of clopidogrel to active form)
|
|
Why is antithrombotic drug contraindicated in neuraxial anesthesia/analgesia?
|
Increased risk of spinal/epidural hematoma leading to spinal cord ischemia and paraplegia
|
|
Dose of enoxaparin in VTE
|
40mg daily, reduced to 30mg if CrCl 20 -30 ml/min
|
|
Risk factors for ICU VTE
|
surgery, major trauma, epo tx, malignancy, sepsis, HF, resp failure, incr. age, immobility, pregnancy, obesity, central line
|
|
T/F, due to long duration, fondaparinux should be avoided in patients with continuous epidural analgesia
|
True
|
|
How long should anticoagulant use be delayed after spinal needle/catheter removed
|
2 hours
|
|
Dose of Enoxaparin in patients at risk for VTE post major trauma or acute spinal cord injury
|
30mg every 12 hours
|
|
Benefits of enteral nutrition in ICU patients
|
reduced risk of infection, improved wound healing, maintained integrity of gut mucosa and reduction in bacterial translocation
|
|
What two meds can promote GI motility and reduce gastric residuals, improving tolerance to EN
|
Metoclopramide and erythromycin
|
|
Preventing Aspiration from EN is accomplished by
|
interrupt if gastric volume is 250 - 5000 ml, head of bed is at 30 - 45 deg, feeding tube placed past pylorus, prokinetic agent
|
|
T/F Late initiation of PN is associated with reduced icu stay, infection, cholestasis, and total health care cost.
|
True. Initiate PN after a one week delay either as a supplement to EN or as sole nutrition
|